. Although there is a little
|
|
- Gillian Bridges
- 5 years ago
- Views:
Transcription
1 PHA 58 Spring 007 Case study 4. Baby girl A, 3kg, 5 days, is receiving phenobarbital because of neonatal seizures. An IV loading dose of phenobarbital sodium of 0mg/kg was given followed by maintenance doses of.5mg/kg every hours. She has a post-load concentration of 4mg/L at hour after the dose. Calculate the baby s volume of distribution. Vd D S F C 0mg / kg 3kg 0.9 4mg.5L.5L / 3kg 0.75L / kg Note: Phenobarbital belongs to anticonvulsant and has a long half-life with 5 days (0h) for adults and.5 days (60h) for children. Bioavailability factor (F) can be assumed to be.0 since this is an IV dose and salt factor (S) is equal to 0.9 for phenobarbital sodium. It is not necessary to use equation Vd D S F k e t C / e. Although there is a little difference between the concentration drawn at hour and the C 0 since very little elimination will occur in such a short time when the drug has a very long half-life. (K0.693/60h0.055h -, C 0 C/e -ket 4/e * 4.8mg/L, Vd.4L which is very close to.5l) The calculation should be used rather than the estimation from population average volume for neonates which is 0.9L/kg to determine the new dose. (0.9L/kg*3kg.7L) The post-load concentration is ideally taken about hour after the loading dose to avoid any distribution phase.
2 . C.B., a 0-year-old, 3 kg female, is receiving valproic acid sprinkles 50 mg ( 5mg) po Q8hr for her seizure disorder. Calculate her valprioc aicd level at steady state. Valproic acid is an anticonvulsant drug. CL0.03L/h/kg for children; 0.008L/h/kg for adults. For bioavailability, except the extended release tablets(f ), all other forms are. Here it is valproic acid sprinkles, F. S Cl(0.03L/h/kg)*(3kg) 0.46L/hr D S F 50mg Cp ss 75.mg Cl τ (0.46L / h) 8h In the clinic, valproic acid C max < 00mg/L, C min > 50mg/L. Here Cpss average is in the range of C max and C min.
3 3. D.W. is a 5-year-old, 70kg male with glomerulonephritis. His creatinine clearance is reasonably good, but he has a low serum albumin concentration of.0g/dl. D.W. is receiving phenytoin and has a steady-state phenytoin concentration of 7mg/L. What would his plasma phenytoin concentration be observed if his serum albumin concentration is normal? (Phenytoin fu 0., normal serum albumin4.4g/dl). Glomerulonephritis is a type of kidney disease that affects the kidneys' filtering function. Cp normal Cp' Patient' salbu min NormalAlbu min ( f ) + f ( 0.) u/ u 7mg.0g / dl g / dl 3.75mg This equation is the most useful when a patient has a low serum albumin concentration but does not have a significantly diminished renal function and is not taking other drugs known to displace phenytoin from plasma protein binding sites. Phenytoin is primarily used as an anticonvulsant and has been used in the treatment of cetain types of cardiac arrhythmias. 3
4 4. P.G, a 50 years old, 80 kg patient, is to be treated p.o. with sodium phenytoin capsules, calculate the following: ). The loading dose to produce an initial concentration of 8 mg/l. How would you administer this dose? ). The daily maintenance dose to produce an average steady state concentration of 5 mg/l. (Please use the key parameters available in the slides.) For phenytoin, Vd0.65 L/kg, K M 4 mg/l, V max 7 mg/kg/day F, S0.9 In the clinic, phenytoin C max < 0mg/L, C min > 0mg/L. Here Cpss average 5 mg/l is in the range of C max and C min. ). Vd 0.65L / kg 80kg 5L Cp Vd 8mg 5L LD 07.39mg 000mg S F 0.9 The 000mg dose is given orally as a 400mg dose followed by two 300mg doses at -hour intervals to decrease the possibility of nausea and vomiting which may be associated with a single large dose. ). MD /day V Cp 7mg / kg / day 80kg 5mg day 0.9 ( K + Cp ) S F ( 4mg + 5mg ) M max ss ss τ mg 480mg 4
5 5. M.K., a 58-year-old, 60 kg female, was admitted to the hospital in status asthmaticus. She received an IV aminophylline loading dose of 375 mg at 9 p.m., followed by a constant aminophylline (dihydrate) infusion of 60 mg/hr. The theophylline concentration was mg/l at 0pm and 6mg/L at 3am. Calculate the apparent clearance and half-life of theophylline in M.K. Assume that the desired steady-state plasma theophylline concentration for M.K. is 5 mg/l, determine whether the maintenance dose needs to be adjusted. (Vd 0.5L/kg) Status asthmaticus is a sudden intense and continuous aggravation of a state of asthma. It is the most severe form of asthma. Vd 0.5L/kg, F, S0.8 (A) Vd 0.5L/kg * 60kg 30L k CL F S ( C + C ) 0 + Vd ( C C ) ( C + C ) ( t t ) 60mg / h L ( 6) mg L / h ( + 6) mg ( + 6) mg 5h Vd L t/ h CL.7L / h C ss F S k mg too high CL.7 Need to decrease the infusion rate. If to maintain M.K.'s theophylline level at 5mg/L, k CL Css.7L / h 5mg 3.5mg / h 3mg / h aminophylline F S dihydrate. Note: Chiou equation is used to calculate clearance for constant rate infusion. Therapeutic plasma concentration is 0-0mg/L for theophylline. 5
PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5128 Final Exam Spring 2004 Version A On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name There are 18 questions. Total /120 pts Final 2004 1 1. T.P., a 66-year-old,
More informationPHA 5128 Spring 2009 First Exam (Version B)
Name: UFID: PHA 5128 Spring 2009 First Exam (Version B) On my honor, I have neither given nor received unauthorized aid in doing this assignment. Print: Sign: Version B Q1: Phenytoin (10) Q2: procainamide
More informationName: UFID: PHA Exam 2. Spring 2013
PHA 5128 Exam 2 Spring 2013 1 Carbamazepine (5 points) 2 Theophylline (10 points) 3 Gentamicin (10 points) 4 Drug-drug interaction (5 points) 5 Lidocaine (5 points) 6 Cyclosporine (5 points) 7 Phenobarbital
More informationPHA 5128 Spring 2000 Final Exam
PHA 128 Spring 2000 Final Exam On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name TYPED KEY Questions Points 1. /1 2. /1 3. /1 4. /1. /10 6. /10. /10 8. /10
More informationPHARMACOKINETICS SMALL GROUP II:
PHARMACOKINETICS SMALL GROUP II: Question 1 Why are some drug therapies initiated with a loading dose? Emphasize that LD establishes initial therapeutic level quickly. The time to reach the steady-state
More informationPHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007
PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007 1. L.J., a 30 year old male, was diagnosed congestive heart failure (CHF). He is 5'9" tall and weights 80 kg. He was given Furosemide
More informationPHA Case Studies V (Answers)
PHA 5128 Case Studies V (Answers) 1. A 100 kg patient is to be treated p.o. with sodium phenytoin capsules. Assuming a phenytoin volume of distribution of 0.7 L/kg, Km of 4 mg/l and Vmax of 7 mg/kg/day,
More informationCarbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8
PHA 5128 Dose Optimization II, Spring 2013, Case Study IV Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More informationBasic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy
Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy I. General principles Applied pharmacokinetics - the process of using drug concentrations, pharmaco-kinetic
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationCLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE
CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE Joseph K. Ritter, Ph.D. Assoc. Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@vcu.edu This self study module will reinforce the
More informationPHA Final Exam Fall 2006
PHA 5127 Final Exam Fall 2006 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationAdjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes
Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationThus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.
PHA 5128 Dose Optimization II, Spring 2012, Case Study V Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationPHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.
PHA 58 ase Study 4 (Answers) Spring 4. PT is a patient stabilized on chronic phenytoin therapy. She has just been diagnosed with rheumatoid arthritis and her physician would like to start her on high dose
More informationLD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)
PHARMKIN WORKSHOP A PHARMACOKINETICS TEACHING SIMULATION Joseph K. Ritter, Ph.D. Associate Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@mail2.vcu.edu Tompkins-McCaw Libray Room 2-006
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationSelected Clinical Calculations Chapter 10. Heparin-Dosing calculations
Selected Clinical Calculations Chapter 10 Heparin-Dosing calculations Heparin is a heterogeneous group of muco-polysaccharides that have anticoagulant properties (slows clotting time). Heparin salt, as
More informationPHA5128 Dose Optimization II Case Study 3 Spring 2013
Use the vancomycin dosing nomogram table below: A female patient, 57 years of age, 5 6 in height and 100 in weight had an infection requiring vancomycin treatment. Her serum creatinine was 0.8 mg/d. What
More informationPHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4120 Second Exam Key Fall 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /10 ponts 2. /20 points 3. /10 points 4. /10 points
More informationCase Study 2 Answers Spring 2006
Case Study 2 Answers Spring 2006 1. The volume of distribution of diazepam in a group of normal subjects (60 kg, ideal body weight) was found to be 105 L. In another group of patients (110 kg), the volume
More informationPHA Final Exam Fall 2001
PHA 5127 Final Exam Fall 2001 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /12 pts 2. /8 pts 3. /12 pts 4. /20 pts 5. /27 pts 6. /15
More informationpharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.
Therapeutic drug monitoring (TDM) Is a tool that can guide the clinician to provide effective and safe drug therapy in the individual patient. Monitoring can be used to confirm a plasma drug concentration
More informationA Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients
CMU. J. Nat. Sci. (2012) Vol. 11(1) 77 A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients Yupaporn Preechagoon 1 and Peeraya Somsaard 2* 1 Department
More informationTDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.
TDM Lecture 7 5 th Stage TDM of Digoxin Digoxin uses and elimination Uses: Digoxin is usually used in heart failure associated and atrial fibrillation. Elimination: About 75% of digoxin clearance occurred
More informationADME Review. Dr. Joe Ritter Associate Professor of Pharmacology
ADME Review Dr. Joe Ritter Associate Professor of Pharmacology 828-1022 jkritter@vcu.edu What percent of a weak base (pka = 7.5) and weak acid (pka = 3.5) will be respectively ionized in urine of ph 5.5?
More informationPHARMACOKINETICS SMALL GROUP I:
PHARMACOKINETICS SMALL GROUP I: Question 1 Absorption of the anti-fungal agent, itraconazole, is dependent on a low gastric ph. Calculate the relative concentrations of a weak acid (with a pka of 5.4)
More informationMyrna Y. Munar, Pharm.D., BCPS
Phenytoin PK Myrna Y. Munar, Pharm.D., BCPS Associate Professor Clickers Turn clicker on by pressing down menu button Enter you OSU student ID number The up/down diagonal arrows button on the left is the
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationDoses Target Concentration Intervention
1 Doses Target Concentration Intervention 2 Problem 1 Questions 1-2 Susan is a 28 year old woman who has had epilepsy since she was 5 years old. She has been on, and off, anticonvulsant medication since
More information4WS Neurology. Table of Contents
4WS Neurology Table of Contents 1. Phenytoin Preparations... Page 2 Monitoring... Page 2 Therapeutic Range... Page 2 Loading Doses... Page 2 Maintenance Doses... Page 3 Sampling Times... Page 3 Dose Adjustment...
More informationPHENYTOIN DOSING INFORMATION. Adult Dosage
PHENYTOIN DRUGDEX Evaluations DOSING INFORMATION Adult Dosage Normal Dosage Important Note ) Due to the risk of severe hypotension and cardiac arrhythmias, the rate of IV phenytoin administration should
More informationPharmacokinetics Applied to the Treatment of Asthma
Pharmacokinetics Applied to the Treatment of Asthma 2016 edition by David C. McMillan, PhD Department of Pharmacology and Experimental Neuroscience College of Medicine University of Nebraska Medical Center
More informationTDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:
Lecture 9: Very important supplements TDM Effect of hepatic disease on drugs monitoring: Generally, hepatic clearance is determined by three main factors: - Liver blood flow (LBF). - Intrinsic capacity
More informationPHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationPHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set
More informationThe importance of clearance
The importance of clearance The calculation of clearance can be especially useful in optimizing dosing of patients The clearance includes both the volume of distribution and the elimination rate The clearance
More informationMultiple IV Bolus Dose Administration
PHARMACOKINETICS Multiple IV Bolus Dose Administration ١ Multiple IV Bolus Dose Administration Objectives: 1) To understand drug accumulation after repeated dose administration 2) To recognize and use
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationRational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell
1 Rational Dose Prediction Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand 2 Pharmacology Pharmacology is derived from a Greek word (pharmakon). The Greeks used
More informationPHAR 7633 Chapter 20 Non Compartmental Analysis
Student Objectives for this Chapter PHAR 7633 Chapter 20 Non Compartmental Analysis To understand and use the non compartmental approach to parameter estimation be able to define, use, and calculate the
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationClinical Pharmacokinetics. Therapeutic Drug Monitoring of Phenytoin
Clinical Pharmacokinetics Therapeutic Drug Monitoring of Phenytoin Dr. Maysa Suyagh School of Pharmacy University of Jordan Phenytoin primarily used as an anticonvulsant and has been used in the treatment
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /150 pts 1 Question Set I (True or
More information6 th Floor and 7 East Nurses Guide Intravenous Drip List Approved for RN Administration University of Kentucky Chandler Medical Center
RATE Abciximab (Reopro) Alteplase (tpa, Activase) All units 6S and 6W ONLY Platelet aggregation inhibitor Thrombolytic agent Bolus: 0.25 mg/kg IV over 5 min Infusion: 0.125 0.9 mg/kg (max 90 mg); 10% of
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationAminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive
Aminoglycosides Uses: Treatment of serious gram-negative systemic infections and some grampositive infections such as infective endocarditis. Disadvantage: aminoglycosides are their association with nephrotoxicity
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More informationPHA First Exam Fall 2003
PHA 5127 First Exam Fall 2003 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /14 pts 2. /6 pts 3. /15 pts 4. /12 pts 5. /20 pts 6. /10pts
More informationPHA First Exam. Fall 2004
PHA 5127 First Exam Fall 2004 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet. If you need to comment or question a problem
More informationProceedings of the World Small Animal Veterinary Association Mexico City, Mexico 2005
Close this window to return to IVIS Proceedings of the World Small Animal Veterinary Association Mexico City, Mexico 2005 Hosted by: Reprinted in the IVIS website with the permission of the WSAVA anticonvulsant
More informationOMCJH.CHEM.COLL.INF.1001 Therapeutic Drug Monitoring Guidelines
OMCJH.CHEM.COLL.INF.1001 Copy of version 1.0 (approved and current) Last Approval or Periodic Review Completed 10/5/2017 Next Periodic Review Needed On or Before 10/5/2019 Effective Date 10/5/2017 Controlled
More informationPrincipal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA
SYNOPSIS Issue Date: 06 October 2008 Document No.: EDMS-PSDB-8954363:2. Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name of Active Ingredient(s)
More informationChildren are small adults and babies are young children
1 Children are small adults and babies are young children Nick Holford Dept Pharmacology & Clinical Pharmacology Brian Anderson Dept Anaesthesia & Starship Hospital University of Auckland, New Zealand
More informationBCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck
More informationNew drugs necessity for therapeutic drug monitoring
New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More informationUncommon Indications for Extracorporeal Toxin Removal (ECTR) Robert S. Hoffman, MD Director, Division of Medical Toxicology NYU School of Medicine
Uncommon Indications for Extracorporeal Toxin Removal (ECTR) Robert S. Hoffman, MD Director, Division of Medical Toxicology NYU School of Medicine Disclosure I have no financial or academic conflicts of
More information1. WHAT OXCARBAZEPINE IS AND WHAT IT IS USED FOR
PACKAGE LEAFLET: INFORMATION FOR THE USER Oxcarbazepine 150/300/600 mg Film-Coated Tablets (Oxcarbazepine) Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You
More informationLearning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD
Learning Outcomes CPPD #7 Clinical Pharmacokine2cs: Concepts and Prac2ce Applica2ons Ahmed Nader, Ph.D, BCPS Ahmed Awaisu, Ph.D, B.Pharm Upon comple;on of this session, audience are expected to be able
More informationManagement of Neonatal Seizures
Management of Neonatal Seizures Manal E. Moustafa Assistant Professor of Pediatric Neurology and Epilepsy Children s Healthcare of Atlanta/Emory University Disclosures I have none! 1 Objectives Recognition
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationSample. Affix patient label within this box.
Instructions for completing orders Complete pages 1-3 for General Inpatient Orders. All pathway compatible orders (indicated by ) within the General Inpatient Orders will be followed automatically. Optional
More informationVolume of Distribution. Objectives. Volume of Distribution
1 Volume of Distribution Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand 2 Objectives Learn the definition of volume of distribution Understand the physiological
More informationNonlinear Pharmacokinetics
Nonlinear Pharmacokinetics Non linear pharmacokinetics: In some cases, the kinetics of a pharmacokinetic process change from predominantly first order to predominantly zero order with increasing dose or
More informationValproate overdose: what is the role of carnitine?
Valproate overdose: what is the role of carnitine? Ruben Thanacoody National Poisons Information Service (Newcastle) Newcastle upon Tyne Hospitals NHS Trust Medical Toxicology Centre, Newcastle University
More informationResuscitation Fluids
Resuscitation Fluids Acceptable Fluids (also known as): Sodium Chloride Hartmann s Solution (Ringer-Lactate Solution, Compound Sodium Lactate) 4.5% Albumin Solution (PPS) Gelofusine 20ml/kg Bolus Can be
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationThe Pharmacokinetics of Antiepileptics Drugs in Neonates with Hypoxic Ischemic Encephalopathy
The Pharmacokinetics of Antiepileptics Drugs in Neonates with Hypoxic Ischemic Encephalopathy KELIANA O MARA, PHARMD FLORIDA NEONATAL NEUROLOGIC NETWORK STATE MEETING Objectives Describe seizures in hypoxic
More informationB. 14 Antidysrhythmic drugs. a. Classify antidysrhythmics by their electrophysiological actions. Vaughan-Williams classification
B. 14 Antidysrhythmic drugs a. Classify antidysrhythmics by their electrophysiological actions. Vaughan-Williams classification I II III IV membrane stabilizers all ERP, ERP/APD, all except c APD classified
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationUSES OF PHARMACOKINETICS
CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program Office of Clinical Research Training and Medical Education National Institutes of Health Clinical Center
More information(Max 2 g) = to nearest 250 mg
Appendix 1 (part 1 of 8): Rubric for competency assessment of pharmacists prescribing and managing vancomycin Empiric Dosing Phase Pts Yes No Data Error OP Did the pharmacist document the indication 2
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane
Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical
More informationThe general Concepts of Pharmacokinetics
The general Concepts of Pharmacokinetics What is this jargon? Is it useful? C max, clearance, Vd, half-life, AUC, bioavailability, protein binding F. Van Bambeke, E. Ampe, P.M. Tulkens (Université catholique
More informationAMINOGLYCOSIDES TDM D O N E B Y
AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.
More informationPharmacokinetics in pediatric population
Pharmacokinetics in pediatric population Children cannot be considered to be small adults. The physiologic processes that determine drug disposition undergo radical changes during biological maturation.
More informationChapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University
Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University Estimating renal function An accurate estimation of renal
More informationCarboplatin + Paclitaxel Cancer of the Cervix
Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they
More informationValproate Case 3: Formulations Jose de Leon, MD
Valproate Case 3: Formulations 2-12-16 Jose de Leon, MD 3.Valproate Case 3 Described in J Clin Psychiatry 2004;65:724-5 http://www.ncbi.nlm.nih.gov/pubmed/15163266 Pharmacological explanation provided
More informationParamedic Pediatric Medical Math Practice
Paramedic Pediatric Medical Math Practice Name: Date: Problem 1 Your 4 year old patient weighs 40 pounds. She is febrile. You need to administer acetaminophen (Tylenol) 15mg/kg. How many mg will you administer?
More informationHow effective is chelation? contrasts in iron and digoxin poisoning. Nick Bateman Edinburgh
How effective is chelation? contrasts in iron and digoxin poisoning Nick Bateman Edinburgh Chelation Chemical chelating agents chemical that bind metal ions and other toxic groups e.g. desferrioxamine
More informationTDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages
TDM Lecture 8 5 th Stage TDM of Digoxin Use of Digoxin Serum Concentrations to Alter Dosages Linear Pharmacokinetics Method This method is used in steady-state condition. We compute the new dose of digoxin
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationDRUGS FOR VIVA. IAP UG Teaching slides
DRUGS FOR VIVA 1 Q:1 INJ SODIUM BICARBONATE 1. What all strengths are available? 2. What are the clinical indications for IV sodium bicarbonate? 3. How do you administer this drug? 2 ANS: 1. Available
More informationDBL MAGNESIUM SULFATE CONCENTRATED INJECTION
DBL MAGNESIUM SULFATE CONCENTRATED INJECTION NAME OF MEDICINE Magnesium Sulfate BP DESCRIPTION DBL Magnesium Sulfate Concentrated Injection is a clear, colourless, sterile solution. Each ampoule contains
More informationAre Pediatric Patients Small Adults?
Are Pediatric Patients Small Adults? Maria Paulina Duarte, Pharm.D. PGY-1 Pharmacy Resident Mercy Hospital A Campus of Plantation General Hospital Goals and Objectives Understand the history and evolution
More informationChildren & Young People s Directorate Paediatric-Neonatal Guidelines Checklist & Version Control Sheet
1 Children & Young People s Directorate Paediatric-Neonatal Guidelines Checklist & Version Control Sheet 1 Name of Guideline / Policy/ Procedure MANAGEMENT OF ACUTE PAEDIATRIC ASTHMA Purpose of Procedure/
More informationPHAR 7632 Chapter 16
PHAR 7632 Chapter 16 Routes of Excretion Routes of Excretion Student Objectives for this Chapter After completing the material in this chapter each student should:- be able to describe the various routes
More informationComplicated Withdrawal
Complicated Withdrawal Shamim Nejad, MD Director, Adult Burns & Trauma Psychiatry Division of Psychiatry and Medicine Medical Director, Addiction Consultation Team MGH Center for Addiction Medicine Massachusetts
More informationRESPIRATORY PHARMACOLOGY - ASTHMA. Primary Exam Teaching - Westmead ED
RESPIRATORY PHARMACOLOGY - ASTHMA Primary Exam Teaching - Westmead ED Sympathomimetic agents MOA: relax airway smooth muscle and inhibit broncho constricting mediators from mast cells May also inhibit
More informationTIP Paclitaxel, Ifosfamide and Cisplatin
Systemic Anti Cancer Treatment Protocol TIP Paclitaxel, Ifosfamide and Cisplatin PROTOCOL REF: MPHATIPGC (Version No: 1.0) Approved for use in: Second line treatment of germ cell tumours Dosage: Drug Dosage
More informationPharmacokinetics Overview
Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak
More information